Identification of a novel TLR5 agonist derived from the P97 protein of Mycoplasma hyopneumoniae.
Immunobiology
; 225(4): 151962, 2020 07.
Article
em En
| MEDLINE
| ID: mdl-32747018
ABSTRACT
By modulating specific immune responses against antigens, adjuvants are used in many vaccine preparations to enhance protective immunity. The C-terminal domain of the protein P97 (P97c) of Mycoplasma hyopneumoniae, which is the etiologic agent of porcine enzootic pneumonia, has been shown to increase the specific humoral response against an antigen when this antigen is merged with P97c and delivered by adenovectors. However, the immunostimulating mechanism of this protein remains unknown. In the present study, recombinantly expressed P97c triggered a concentration-dependent TLR5 activation and stimulates the production of interleukin-8 from HEK-Blue mTLR5 cells. Circular dichroism spectroscopy and prediction of 3-dimensional conformation exposed a relevant secondary and tertiary structural homology between P97c and flagellin, the known potent TLR5 agonist. P97c adjuvanticity was evaluated by fusing the conserved epitope of the ectodomain matrix 2 protein (M2e) of the influenza A virus to the protein. Mice immunized with P97c-3M2e revealed a high antibody titer against the M2e epitope associated with a mixed Th1/Th2 immune response. Overall, this study identifies a novel agonist of the pattern recognition receptor TLR5 and reveals that P97c is a potential adjuvant through the activation of the innate immune system.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Adesinas Bacterianas
/
Mycoplasma hyopneumoniae
/
Pneumonia Suína Micoplasmática
/
Receptor 5 Toll-Like
/
Interações Hospedeiro-Patógeno
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article